Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects

Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T · Frontiers in Nutrition

Whole-blood NAD+ rose significantly against placebo with no abnormalities in physiological or laboratory tests. Blood NMN itself did not rise, while nicotinic acid mononucleotide did — a clue that oral NMN reaches NAD+ by an indirect route.

Population

Healthy adult volunteers

Intervention

NMN 250 mg/day for 12 weeks

Comparator

Placebo

Limitations

Fifteen per arm, healthy volunteers, biochemical endpoints only; no functional or clinical outcome was measured. The sample size was calculated for adverse events at a 0.10 significance level and 0.70 power, so the trial was built to test safety rather than to detect an effect. Funded by the NMN manufacturer, four of six authors its employees, who prepared both the product and the placebo.